| International Myeloma Working Group molecular classification of multiple myeloma: spotlight review R Fonseca, PL Bergsagel, J Drach, J Shaughnessy, N Gutierrez, ... Leukemia 23 (12), 2210-2221, 2009 | 1182 | 2009 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1007 | 2012 |
| Clinical and biologic implications of recurrent genomic aberrations in myeloma R Fonseca, E Blood, M Rue, D Harrington, MM Oken, RA Kyle, ... Blood 101 (11), 4569-4575, 2003 | 909 | 2003 |
| Managing incidental findings in human subjects research: analysis and recommendations SM Wolf, FP Lawrenz, CA Nelson, JP Kahn, MK Cho, EW Clayton, ... Journal of Law, Medicine & Ethics 36 (2), 219-248, 2008 | 854 | 2008 |
| Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation BGM Durie, RA Kyle, A Belch, W Bensinger, J Blade, M Boccadoro, ... The Hematology Journal 4 (6), 379-398, 2003 | 621 | 2003 |
| Managing incidental findings and research results in genomic research involving biobanks and archived data sets SM Wolf, BN Crock, B Van Ness, F Lawrenz, JP Kahn, LM Beskow, ... Genetics in Medicine 14 (4), 361-384, 2012 | 504 | 2012 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Myeloma and the t (11; 14)(q13; q32); evidence for a biologically defined unique subset of patients R Fonseca, EA Blood, MM Oken, RA Kyle, GW Dewald, RJ Bailey, ... Blood, The Journal of the American Society of Hematology 99 (10), 3735-3741, 2002 | 409 | 2002 |
| ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products. BG Van Ness, JB Howard, JW Bodley Journal of Biological chemistry 255 (22), 10710-10716, 1980 | 393 | 1980 |
| Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial P Liu, T Leong, L Quam, D Billadeau, NE Kay, P Greipp, RA Kyle, ... | 302 | 1996 |
| The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. D Billadeau, G Ahmann, P Greipp, B Van Ness The Journal of experimental medicine 178 (3), 1023-1031, 1993 | 284 | 1993 |
| ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. BG Van Ness, JB Howard, JW Bodley Journal of Biological Chemistry 255 (22), 10717-10720, 1980 | 252 | 1980 |
| Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the … PR Greipp, T Leong, JM Bennett, JP Gaillard, B Klein, JA Stewart, ... Blood, The Journal of the American Society of Hematology 91 (7), 2501-2507, 1998 | 244 | 1998 |
| Transcription of the unrearranged mouse Cκ locus: sequence of the initiation region and comparison of activity with a rearranged Vκ-Cκ gene BG Van Ness, M Weigert, C Coleclough, EL Mather, DE Kelley, RP Perry Cell 27 (3), 593-602, 1981 | 233 | 1981 |
| Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: an Eastern … R Fonseca, D Harrington, MM Oken, GW Dewald, RJ Bailey, SA Van Wier, ... Cancer Research 62 (3), 715-720, 2002 | 227 | 2002 |
| Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients D Billadeau, L Quam, W Thomas, N Kay, P Greipp, R Kyle, MM Oken, ... | 223 | 1992 |
| Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy R Fonseca, MM Oken, D Harrington, RJ Bailey, SA Van Wier, ... Leukemia 15 (6), 981-986, 2001 | 216 | 2001 |
| Clinical and biological significance of RAS mutations in multiple myeloma WJ Chng, N Gonzalez-Paz, T Price-Troska, S Jacobus, SV Rajkumar, ... Leukemia 22 (12), 2280-2284, 2008 | 207 | 2008 |
| The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype PA Croonquist, B Van Ness Oncogene 24 (41), 6269-6280, 2005 | 197 | 2005 |
| Clinical significance of TP53 mutation in myeloma WJ Chng, T Price-Troska, N Gonzalez-Paz, S Van Wier, S Jacobus, ... Leukemia 21 (3), 582-584, 2007 | 177 | 2007 |
